Let's look at why this news could be a game-changer for Eli Lilly and its stock.

Eli Lilly's oral GLP-1 drug orforglipron showed strong Phase 3 results with 7.9% weight ... So, Eli Lilly appears to have solid liquidity for the next twelve months. Long-term debt was $28.644 ...

The market for anti-obesity drugs has been growing for a while, but is finally about to take off with the entry of two global ...

Domestic contract manufacturing organizations (CMOs) are also making efforts to seize the obesity drug ... phase 3 clinical trial. In July last year, U.S. Pfizer resumed the development of the ...

2024 saw the first FDA approval of a cancer cell therapy that tackles solid tumours ... pre-registration phase waiting for a regulatory decision. Of these, 20% were GLP-1 drugs alone, with ...

In the first of several readouts expected from a Phase III programme, Lilly said its oral glucagon-like peptide-1 ... as “solid”. This data readout was viewed as a closely watched event, and all eyes ...

Therapeutic peptides like semaglutide and tirzepatide, GLP-1 agonists marketed under brand names such ... The current leading therapeutic peptide manufacturing method, known as solid-phase peptide ...